The clinical stage biopharmaceutical company said Dickey had extensive experience in private and public healthcare companies.
Before joining Motif he was CFO at Tyme Technologies Inc, a US-listed company valued at around US$180mln.
Dickey will replace Pete Meyers, who is leaving Motif, though he will hang around to help with the hand-over to Dickey.
"I am delighted that Rob has agreed to join Motif Bio at this important time as we await data read-out in the second quarter of 2017 from REVIVE-1, our Phase 3 clinical trial in patients with ABSSSI (Acute Bacterial Skin and Skin Structure Infections),” said Graham Lumsden, chief executive officer of Motif..
“Rob's proven leadership and strategic skills will be a tremendous addition to the team. I am immensely grateful to Pete Meyers for his tireless dedication and hard work during 2016, culminating in a successful NASDAQ IPO and raise of $25 million. I wish him well in his future endeavours," he added.
“Robert is a strong addition to the Motif team, particularly due to his considerable experience in the biotech sector. Also, his NASDAQ experience will prove useful to the company given its recent dual-listing on the market,” suggested Vadim Alexandre, at Northland Capital Partners.